University of Ioannina
Μελέτη της έκφρασης και της κλινικής σημασίας των κυκλινών και της μεθυλίωσης των ανασταλτών τους στις αιματολογικές κακοήθειες
Abstract
dc:descriptionAim of this study was to study the expression of type D cyclins and the methylation status of genes that are involved in cell cycle regulation pathways (CDKN2B, CDKN2A,CDKN1C, TP73, Snk/plk2, VHL) in patients with monoclonal gammopathies. Patients and methods: We studied 45 patients with multiple myeloma (MM), 4 patients with Waldenstrom's macroglobulinemia (WM), and 3 patients with monoclonal gammopathy of undetermined significance (MGUS). Quantitative RT-PCR was employed for the cyclin expression. Methylation status of each gene was analysed by methylation-specific PCR (MSP). Logistic regression analysis where gene methylation status at diagnosis was used as a single predictor variable to measure associations with the development of anemia, advanced stage disease, extramedullary disease and bone disease (all as the dependent variables). Survival curves were generated using the method of Kaplan-Meier and compared with the log-rank test. Results: Increased expression of D type cyclins was noted in MM patients. Cyclin D1 levels were significantly higher to cyclin D2 levels (p=0.01) and cyclin D3 (p=0.004). Interesting associations were noted between cyclin expression levels and relevant clinical parameters but no significant prognostic value was found. Methylation of the p15 (CDKN4B) and p16 (CDKN4A) was found in 28% and 31 % of MM patients respectively. Patients methylated for p16 were more likely to have advanced stage disease and anemia at diagnosis and had an increased risk of death, but p values did not reach significance. Methylation of p16 was not found to be a predictor of bone or extramedullary disease. Patients methylated for the p15 promoter were more likely to have anemia at diagnosis (p>0.05). No association was found between p15 methylation status and bone or extramedullary disease or overall survival. No patient was found to be methylated for CDKN1C and TP73. Methylation of the VHL promoter was found in 41 % of MM patients. Patients methylated for VHL showed an increased risk of death (HR=1.3, p=0.6), anemia (OR=2, p=0.2), extramedullary disease (OR=2.3, p=0.22) and significantly increased risk of developing development of lytic bone disease (OR =6.5, p=0.029). Snk/plk2 methylation was noted in 60% and 75% of MM and WM patients respectively. No significant association was found between snk/plk2 methylation and clinical parameters. In summary, cyclins are overexpressed in MM, but they do not hold a significant prognostic value. Genes involved in cell cycle regulation are found to be methylated in MM and WM. Several interesting trends were noted between the genes methylation status and relevant clinical parameters. These findings warrant further evaluation in a larger sample of patients in order to enhance our statistical power and better define the prognostic value of each gene's methylation status in these diseases.
Degree
thesis:*- Grantor dc:publisher
- University of Ioannina
- Year dc:date
- 2008
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Χατζημιχαήλ, Ελευθερία
- Hatzimichael, Eleftheria
Subjects
dc:subject × 20- Κυκλίνες
- Αιματολογικές κακοήθειες
- Μεθυλίωση
- Επιγενετική
- Μυέλωμα, Πολλαπλό
- Αναστολείς κυκλινών
- Κυτταρικός κύκλος
- Πλασματοκυτταρικές δυσκρασίες
- Cyclins
- Haematological malignancies
- Methylation
- Epigenetics
- Multiple myeloma
- Cyclin inhibitors
- Cell cycle
- Plasma cell dyscrasias
- Ιατρική και Επιστήμες Υγείας
- Βασική Ιατρική
- Medical and Health Sciences
- Basic Medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/21547